Presentations
17. GTU as Benficial HIV DNA Vaccine Vector System
Andres Männik1, Rein Sikut1, Katrin Kaldma1, Urve Toots1, Tarmo Mölder1, Kaja Kiiver1, Maarja Adojaan1, Anu Remm1, Evelin Täht1, Helle Remme1 and Mart Ustav1
1 FIT Biotech Oy Eesti AS, Tartu, ESTONIA
2 FIT Biotech Oy, Tampere, FINLAND
Conference: AIDS Vaccine 2009, Paris 19-22 October
16. Efficay study of a T-cell-based DNA vaccine delivered by intradermal electrotransfer in macacques
N. Dereuddre-Bosquet1, M. Baron1, I. Mederle-Mangeot1, K. Kaldma2, R. Sikut2, A. Männik2, M. Ustav2, I. Stanescu3, R. Le Grand1 and F. Martinon1
1 Service d’Immuno-Virologie, CEA, Fontenay aux Roses, France
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia
3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: AIDS Vaccine 2009, Paris 19-22 October
15. A Novel Plasmid DNA Technology (GTU®) Applied As A Potential HIV1/AIDS Therapeutic Vaccine
Eftyhia Vardas1, Clive Gray2, Ioana Stanescu3, Blazevic Vesna3, Valtavaara Minna3, Mika Leinonen4, Mart Ustav5,6 and Kalevi Reijonen3
1 University of Witwatersrand, Perinatal HIV Research Unit, Soweto, Johannesburg, South Africa
2 National Institute of Communicable Diseases, Johannesburg, South Africa
3 FIT Biotech Plc, Tampere, Finland
4 Pharma Turku Finland
5 FIT Biotech Plc, Tartu, Estonia
6 Institute of Technology, University of Tartu
Conference: Vaccine Congress. December 2008, Boston, USA
14. Induction of Persistent T Cell Responses against HIV in Macaques with a Multivalent DNA Vaccine Injected Intradermaly with Electroporation
F. Martinon1, R. Sikut2, J. Morin1, I. Picq1, K. Kaldma2, M. Ustav2, I. Stanescu3 and R. Le Grand1
1 Service d’Immuno-Virologie, CEA, Fontenay aux Roses, France
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia
3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: Vaccine Congress. Celebrating 25 years of Publication. 9-11 Decembre 2007. Amsterdam, The Netherlands
13. Induction of persistent multifunctional T cell responses against HIV in macaques with a multi-antigen DNA vaccine injected intradermaly with electroporation
F. Martinon, R. Sikut, J. Morin, I. Picq, K. Kaldma, M. Ustav, I. Stanescu and R. Le Grand
Conference: Keystone Symposia: Challenges of Global Vaccine Development (T1-2007)
Conference Location: Cape Town, South Africa
Date: 2007/10/08-2007/10/13
12. Immunogenicity and clinical effects of GTU-MultiHIV B clade DNA vaccine in treatment-naïve HIV-infected subjects
E. Vardas5, I. Stanescu1, V. Blazevic1, K. Frisk2, G. Chiba5, T. Makgopane5, M. Valtavaara1, G. Khoury3, C. Gray4, L. Morris4, T. Kuntonen1 and M. Leinonen1
1 FIT Biotech Plc Tampere, Finland
2 FIT Biotech Plc Tartu, Estonia
3 National Institute of Communicable Diseases, Johannesburg, South Africa
4 Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
Conference: AIDS Vaccine 2007, August 20-23, Seattle, Washington USA
11. Induction of persistent mutlifunctional T-cell responses with a multi-antigen DNA vaccines injected intradermally with electroporation in macaques
F. Martinon1, R. Sikut2, I. Picq1, J. Morin1, K. Kaldma2, M. Ustav2, I. Stanescu3 and R. Le Grand1
1 Service d’Immuno-Virologie, CEA, Fontenay aux Roses, France
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia
3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: AIDS Vaccine 2007, August 20-23, Seattle, Washington USA
10. Induction of Persistent Multifuctional anti-HIV T Cell responses with a multivalent DNA vaccine injected intradermally in cynomolgous macaques
F. Martinon1, R. Sikut2, I. Picq1, J. Morin1, K. Kaldma2, M. Ustav2, I. Stanescu3 and R. Le Grand1
1 Service d’Immuno-Virologie, CEA, Fontenay aux Roses, France;
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia
3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: 1st internatinal symposium on genetic and immune correlates of HIV infection and vaccine-induced immunity, June 10-13, 2007, Budapest, Hungary
9. Induction of persistent multifunctional T cell responses against several HIV antigens in macaques with a multivalent DNA vaccine injected intradermaly with electroporation
F. Martinon1, R. Sikut2, J. Morin1, I. Picq1, K. Kaldma2, M. Ustav2, I. Stanescu3, and R. Le Grand1
1 Service d’Immuno-Virologie, CEA, Fontenay aux Roses, France
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia; 3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: 25th Annual Symposium on Nonhuman Primate Models for AIDS, Monterey, California, September 10-13, 2007
8. Immunogenecity of a multi-antigen pDNA vaccine is improved significantly after in vivo electroporation of the injection site in skin of cynomolgus macaques
R. Sikut2, F. Martinon1, K. Kaldma2, I. Picq1, F. Le Goff1, H. Remme2, M. Ustav2, I. Stanescu3, and R. Le Grand1
1 Service de Neurovirologie, CEA, Fontenay aux Roses, France
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia; 3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: DNA Vaccines 2007, Malaga, Spain, 23-25 May 2007-11-07
7. Immunogenicity of a multiepitope multivalent DNA vaccine against HIV-1 in cynomolgus macaques
F. Martinon1, I. Picq1, H. Moussu1, F. Le Goff1, R. Sikut2, K. Kaldma2, H. Remme2, M. Ustav2, I. Stanescu3 and R. Le Grand1
1 Service de Neurovirologie, CEA, Fontenay aux Roses, France;
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia; 3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: AIDS Vaccine 2006, 29-aug-1 Sept 2006, Amsterdam
6. Vaccination with a Multivalent DNA encoding for several HIV-1 proteins induces long lasting immunity in cynomolgous macaques
F. Martinon1, I. Picq1, H. Moussu1, F. Le Goff1, R. Sikut2, K. Kaldma2, H. Remme2, M. Ustav2, I. Stanescu3 and R. Le Grand1
1 Service d’Immuno-Virologie, CEA, Fontenay aux Roses, France
2 FIT Biotech Oyj Plc Eesti AS, Tartu, Estonia
3 FIT Biotech Oyj Plc, Tampere, Finland
Conference: 24th Annual Symposium on Nonhuman Primate Models for AIDS. Atlanta, Georgia, USA, Oct. 4-7, 2006
5. Preclinical evaluation of the multiepitope multivalent DNA vaccine against HIV using three different animal models
Rein Sikut1, Andres Männik1, Katrin Kaldma1, Helle Remme1, Urve Toots1, Anu Remm1, Maria Malm2, Vesna Blazevic2, Helene Moussu3, Frederick Le Goff3, Frederic Martinon3, Roger Le Grand3, Ioana Stanescu2 and Mart Ustav1
1 FIT Biotech Oyj Plc Eesti AS
2 FIT Biotech OyJ Plc Tampere, Finland
3 Service de Neurovirologie, Commissariat a l’Energie Atomique, France
Conference: Molecular & Immunological approaches to vaccine design, Cold Spring Harbour Laboratory, New York, December 1-4, 2005
4. HIV-1 DNA immunogens expressing multiple genes and epitopes from subtypes A, B, C and FGH induce cross-clade protection in experimental challenge
Maria Malm1, Erik Rollman2, Vesna Blazevic1, Toomas Kivisild3, Maarja Adojaan3, Andres Männik3, Urve Toots3, Rein Sikut3, Minna Valtavaara1, Kai Krohn1, Jorma Hinkula2, Britta Wahren2, and Mart Ustav3
1 FIT Biotech Plc Tampere, Finland
2 Swedish Institute for Infectious Diseases Control and Karolinska Institutet
3 FIT Biotech Plc Tartu, Estonia
Conference: Keystone Symposium: HIV Vaccines: Current Challenges and Future Prospects, April 9-15, 2005, Alberta, Canada
3. Development of a multiepitope/multiclade HIV DNA vaccine; results from preclinical and clinical trials
Kai Krohn1, Mart Ustav2, Ioana Stanescu1, Vesna Blazevic1, Maria Malm1, Minna Valtavaara1, Andres Männik2, Urve Toots2, Rein Sikut2, Maarja Adojaan2,Toomas Kivisild3, Tytti Kärkkäinen1, Kari Laurikainen1, Annamari Ranki4
1 FIT Biotech Plc Tampere, Finland
2 FIT Biotech Plc Tartu, Estonia
3 Estonian Biocenter, Tartu, Estonia
4 Helsinki University Central Hospital, Helsinki, Finland
Conference: Keystone Symposium: HIV Vaccines: Current Challenges and Future Prospects, April 9-15, 2005, Alberta, Canada
2. Predominance of a rare type of HIV-1 in Estonia
Maarja Adojaan1,2, Toomas Kivisild3, Andres Männik1, Tõnu Krispin4, Kai Krohn1, Richard Villems2,3, Mika Salminen5, Mart Ustav1,6
1 FIT Biotech Plc, Tampere, Finland and Tartu, Estonia
2 Department of Evolutinary Biology, Institute of Molecular and Cell Biology, University of Tartu, Estonia
3 Estonian Biocentre, Tartu, Estonia
4 Institute of Microbiology, University of Tartu, Estonia
5 HIV-Laboratory, Department of Infectious Disease Epidemiology, National Public Health Institute, Helsinki, Finland
6 Institute of Technology, University of tartu, Estonia
Conference: The 11th International Workshop on HIV Dynamics and Evolution, April 29 - May 2, 2004 Stockholm, Sweden
1. Development of a multiepitope/multiclade HIV DNA vaccine; results from preclinical and clinical trials
Kai Krohn1, Mart Ustav2, Ioana Stanescu1, Vesna Blazevic1, Maria Malm1, Minna Valtavaara1, Andres Männik2, Urve Toots2, Rein Sikut2, Maarja Adojaan2, Toomas Kivisild3, Tytti Kärkkäinen1, Kari Laurikainen1, Annamari Ranki4
1 FIT Biotech Plc, Biokatu 8, 33520, Tampere, Finland
2 FIT Biotech Plc, Tartu, Estonia
3 Estonian Biocenter, Tartu, Estonia
4 Helsinki University Central Hospital, Helsinki, Finland
Conference: DNA Vaccines 2004, Monaco, November 2004
E-mail
